NCT06108479 2026-03-18
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1 Completed
Clinical Trials
482 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT07481123 2026-03-18
COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT
University of Gaziantep
Phase NA Completed
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02121730 2026-03-16
FRISC
Centre Hospitalier Universitaire, Amiens
Completed
NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT01596816 2026-03-13
CKNO-PRO
Centre Oscar Lambret
Phase 2 Completed
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT01804712 2026-03-12
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
University of California, San Diego
Phase EARLY_PHASE1 Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT07464964 2026-03-11
MUSIC-PRT
Dokuz Eylul University
Phase NA Completed
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00034424 2026-03-09
Cause of Familial Testicular Cancer
National Institutes of Health Clinical Center (CC)
Completed
NCT05162846 2026-03-09
MiGHT
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT00160979 2026-03-06
Transrectal Tumour Oxygen - US Army
University Health Network, Toronto
Phase 2 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01567800 2026-03-06
Prostate Hypoxia FAZA
University Health Network, Toronto
Phase NA Completed
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT05764005 2026-03-06
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT06184867 2026-03-06
CATALYST
Rutgers, The State University of New Jersey
Phase NA Completed
NCT00063882 2026-03-05
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01104350 2026-03-05
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT05008900 2026-03-05
TOPP
University Health Network, Toronto
Phase 2 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT07448545 2026-03-05
Turkish Version of the UCLA Prostate Cancer Index
Lokman Hekim University
Completed
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT06472856 2026-03-04
VASA Pro
University College Cork
Phase NA Completed
NCT03348969 2026-03-03
NICSA
Aarhus University Hospital
Phase 4 Completed
NCT06281691 2026-03-03
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
Aarhus University Hospital
Completed
NCT07445451 2026-03-03
TURBT
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Phase NA Completed
NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT04443062 2026-02-27
Bullseye
Radboud University Medical Center
Phase 2 Completed
NCT04610671 2026-02-27
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT05858749 2026-02-27
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Pfizer
Completed
NCT06549634 2026-02-27
Biomarkers of AKI in Patients Receiving Daratumumab
Brigham and Women's Hospital
Completed
NCT07436169 2026-02-27
2D:4D Finger Ratio and Breast Cancer in Women
Malatya Turgut Ozal University
Completed
NCT07436416 2026-02-27
EXO-RENAL2
Institute of Oncology Ljubljana
Phase NA Completed
NCT03159676 2026-02-25
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
Mayo Clinic
Completed
NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT03568188 2026-02-24
FOCALE
Hospices Civils de Lyon
Phase 2 Completed
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT00699751 2026-02-23
ALSYMPCA
Bayer
Phase 3 Completed
NCT03388619 2026-02-23
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02899221 2026-02-20
Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation
Thomas Jefferson University
Phase NA Completed